1.Reliability and validity of Chinese version of Diabetes Continuity of Care Scale
Chinese Journal of Practical Nursing 2015;31(22):1674-1677
Objective To translate the English version of Diabetes Continuity of Care Scale (DCCS) into Chinese and to test the reliability and validity of the Chinese version of DCCS in diabetes mellitus patients.Methods Totally 245 patients with diabetes mellitus were recruited and were investigated by the Chinese version of DCCS.Results The internal consistency coefficient of the Chinese version of DCCS ranged from 0.728 to 0.942,which was >0.70;split half coefficient r=0.784,and the test-retest was 0.864 while which of each dimension ranged from 0.785 to 0.886.The content validity index was 0.934.Factor analysis got five factors,which explained 76.574% of the total variance;the factor loading of each item was >0.4.Conclusions The Chinese version of DCCS has been proved to be reliable and valid.It can be used as a valid tool for the measurement of continuity of care in patients with diabetes mellitus.
2.Reliability and validity of Chinese version of the Medication Adherence Self-efficacy Scale
Chinese Journal of Practical Nursing 2015;31(20):1502-1505
Objective To translate the English version of the Medication Adherence Self-efficacy Scale (MASES) into Chinese and to test the reliability and validity of the Chinese version of MASES in patients with hypertension.Methods Totally 285 patients with hypertension were recruited and were investigated by the Chinese version of MASES.The results underwent analysis for reliability and validity.Results The retest reliability of MASES was 0.843.The Cronbach α of the Chinese version of MASES was 0.876.The Cronbach α of the four dimensions ranged from 0.794 to 0.905.The average content vality index (CVI) of the scale was 0.946.Factor analysis got four factors,which explained 68.683% of the total variance.The factor loading of each item on its common factor was >0.4.Conclusions The Chinese version of MASES has been proved to be reliable and valid.It can be used as a valid tool for the measurement of the patient compliance in patients with hypertension.
3.Reliability and validity of Chinese version of the Oncology Patients' Perceptions of the Quality of Nursing Care Scale
Chinese Journal of Practical Nursing 2015;31(23):1770-1773
Objective To translate the English version of the Oncology Patients' Perceptions of the Quality of Nursing Care Scale (OPPQNCS) into Chinese and to test the reliability and validity of the Chinese version of OPPQNCS in oncology patients.Methods The English version of OPPQNCS was translated by Brislin translation mode.Totally 320 oncology patients were recruited and were investigated by the Chinese version of OPPQNCS.Results The internal consistency coefficient of the Chinese version of OPPQNCS was more than 0.70,ranged from 0.804 to 0.964;the test-retest was 0.826.The content validity index(CVI) was 0.845-1.000,the average CVI was 0.925.Factor analysis got four factors,which explained 78.548% of the total variance.And every objective factor loading were greater than 0.4.Conclusions The Chinese version of OPPQNCS has been proved to be reliable and valid.It can be used as a valid tool for the oncology patients to measure their perceptions of the quality of nursing care they got.
4.Reliability and validity of Chinese version of the Client-Centred Care Questionnaire
Shuxia LIU ; Yueqin CHEN ; Fuling FAN
Chinese Journal of Practical Nursing 2015;31(19):1460-1463
Objective To translate the English version of the Client-Centred Care Questionnaire (CCCQ) into Chinese and to test the reliability and validity of the Chinese version of CCCQ.Methods The English version of CCCQ was translated into Chinese by the method of double translation-translation.Totally 320 chronic patients were recruited and they were investigated by the Chinese version of CCCQ.Results The Cronbach coefficient of the Chinese version of CCCQ was 0.925,P<0.01.The retest reliability was 0.807,P<0.01.The split-half reliability with r=0.883,P<0.01.The content validity index (CVI) was 0.956,and every purpose CVI values were above 0.8.Factor analysis got one factor,which explained 52.549% of the total variance,and each objective factor loading was above 0.4.Conclusions The Chinese version of CCCQ has been proved to be reliable and valid.It can be used as a valid tool for the chronic patients to measure their perceptions of the quality of nursing care.
5.Diagnosis and genetic analysis of severe neonatal anemia caused by α-Thalassemla combined with cold IgG anti-M
Fuling ZHONG ; Yuqing SU ; Fan WU ; Shuang LIANG ; Yanlian LIANG
Chinese Journal of Blood Transfusion 2022;35(12):1266-1269
【Objective】 To investigate the family inheritance of α-Thalassemla gene and the risk of severe anemia in neonates caused by cold IgG anti-M. 【Methods】 ABO, Rh, MN blood groups and the specificity of unexpected antibody were identified by blood group serology. The IgG subtype and antibody titer of anti-M antibody were detected. The etiology of neonatal hemolytic disease was identified by three tests and α-Thalassemla gene diagnosis. 【Results】 Family investigation showed that father was B, CCDee, MN with no α-Thalassemla gene detected; Mother B, CcDee, NN, carrying α-Thalassemla gene; both the proband and his brother were B, CCDee, MN, carrying α-Thalassemla gene. Cold IgG anti-M was present in plasma of both the mother and the proband. The titer of the mother was 128 and that of the proband was 64. The subtype of IgG anti-M was IgG1 and IgG3. The direct anti-globulin test, release test and free test of the proband and his brother were negative, and the diagnosis was severe anemia and hemolysis caused by α-Thalassemla combined with cold IgG anti-M. 【Conclusion】 The direct antiglobulin test of neonatal hemolytic disease caused by IgG anti-M can be negative or weakly positive, and α-Thalassemla gene could be hereditary in families. The presence of α-Thalassemla gene can cause anemia, hemolysis and splenomegalysis in neonates, which could be aggravated when accompanied by cold-type IgG anti-M. In the presence of high-valency IgG antibody in plasma, blood exchange combined with transfusion can improve the curative effect.
6.Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19.
Xiaoyan LIU ; Zhe LI ; Shuai LIU ; Jing SUN ; Zhanghua CHEN ; Min JIANG ; Qingling ZHANG ; Yinghua WEI ; Xin WANG ; Yi-You HUANG ; Yinyi SHI ; Yanhui XU ; Huifang XIAN ; Fan BAI ; Changxing OU ; Bei XIONG ; Andrew M LEW ; Jun CUI ; Rongli FANG ; Hui HUANG ; Jincun ZHAO ; Xuechuan HONG ; Yuxia ZHANG ; Fuling ZHOU ; Hai-Bin LUO
Acta Pharmaceutica Sinica B 2020;10(7):1205-1215
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause acute respiratory distress syndrome, hypercoagulability, hypertension, and multiorgan dysfunction. Effective antivirals with safe clinical profile are urgently needed to improve the overall prognosis. In an analysis of a randomly collected cohort of 124 patients with COVID-19, we found that hypercoagulability as indicated by elevated concentrations of D-dimers was associated with disease severity. By virtual screening of a U.S. FDA approved drug library, we identified an anticoagulation agent dipyridamole (DIP) , which suppressed SARS-CoV-2 replication . In a proof-of-concept trial involving 31 patients with COVID-19, DIP supplementation was associated with significantly decreased concentrations of D-dimers ( < 0.05), increased lymphocyte and platelet recovery in the circulation, and markedly improved clinical outcomes in comparison to the control patients. In particular, all 8 of the DIP-treated severely ill patients showed remarkable improvement: 7 patients (87.5%) achieved clinical cure and were discharged from the hospitals while the remaining 1 patient (12.5%) was in clinical remission.